ALBUQUERQUE, N.M., Oct. 4 /PRNewswire-FirstCall/ -- Biomoda, Inc. (http://www.biomoda.com) of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology, announced today an agreement with Averion International Corporation of Southborough, Mass. to provide a range of clinical services including protocol design and study implementation for Biomoda’s clinical programs.
“Averion is a global clinical research organization that offers the broad range of services required of a company like Biomoda that is looking to enter the world market,” said John Cousins, President of Biomoda. “As a clinical research organization, Averion can rapidly deliver world-class study design, protocol development and clinical trial implementation. Equally important, Averion has the most enviable track record for FDA approvals in the industry.”
Averion (http://www.averionintl.com) is a leading Clinical Research Organization (CRO) with a heritage and depth in pharmaceutical, biotechnology, and medical devise trials across a wide range of indications. It is a globally preeminent CRO with a focus in oncology, dermatology, nephrology, and medical devices and offers comprehensive understanding of what it takes to efficiently manage clinical trials from Phase I-IV through to post-marketing studies, safety surveillance and patient registries.
Biomoda’s technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope. The patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.
Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.
Contact: John Cousins
CONTACT: John Cousins, +1-505-821-0875, for Biomoda, Inc.
Web site: http://www.biomoda.com/
http://www.averionintl.com/
